Kyowa Hakko Kirin Co., Ltd. (4151)

2,730.0
+55.0(+2.06%)
  • Volume:
    896,000
  • Bid/Ask:
    2,729.0/2,733.0
  • Day's Range:
    2,684.0 - 2,735.0
  • Type:Equity
  • Market:Japan
  • ISIN:JP3256000005

4151 Overview

Prev. Close
2,675
Day's Range
2,684-2,735
Revenue
358.88B
Open
2,710
52 wk Range
2,604-4,240
EPS
103.19
Volume
896,000
Market Cap
1.47T
Dividend (Yield)
47.00
(1.72%)
Average Vol. (3m)
973,330
P/E Ratio
26.46
Beta
0.78
1-Year Change
-17.52%
Shares Outstanding
537,372,927
Next Earnings Date
Aug 04, 2022
What is your sentiment on Kyowa Hakko Kirin?
or
Market is currently closed. Voting is open during market hours.

Kyowa Hakko Kirin Co., Ltd. News

Kyowa Hakko Kirin Co., Ltd. Company Profile

Kyowa Hakko Kirin Co., Ltd. Company Profile

Employees
5752
Market
Japan

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuySellNeutral
Technical IndicatorsSellStrong BuyStrong BuySellStrong Sell
SummaryNeutralStrong BuyStrong BuySellSell